

November 22, 2016 – All Networks

**A L E R T**

## Testing for Urine Reducing Substances to be discontinued due to lack of reagent availability

The sole national supplier of reagent for urine reducing substances (Bayer) has permanently discontinued the manufacture of Clinitest tablets used for urine reducing substance testing.

In recent years, the demand for this testing at our laboratories has dropped to near zero, since screening for galactosemia is now included with routine newborn blood spot testing which is now mandated in all 50 states. That method is both more sensitive and specific than the urine screening method. Other disorders of carbohydrate metabolism are rare and generally more benign clinically.

Current screening guidelines now recommend against use of the Clinitest method (or any similar method) for carbohydrate metabolism disorders.<sup>1,2</sup> The College of American Pathologists (CAP) supports that recommendation.<sup>3</sup>

For these reasons, testing for Urine Reducing Substances (LAB554) will be unavailable effective immediately from PeaceHealth Laboratories. Referred testing for galactosemia (GALT) mutations and/or enzyme activity is available from ARUP laboratories if desired.

Feel free to contact us with any questions about this or other testing.

### QUESTIONS

**Michael Suter, MT**

Senior Clinical Scientist, Hematology

541-687-2134 ext. 8182

800-826-3616 ext. 8182

541-968-4917 cell

msuter@peacehealthlabs.org

**Berle Stratton, MD**

System Medical Director

360-514-2237

bstratton2@peacehealthlabs.org

1. Naumova NN, Schappert J, Kaplan LA. Reducing substances in urine: a paradigm for changes in a standard test. *Ann Clin Lab Sci.* 2006;36(4):447–448.
2. Walter JH, Collins JE, Leonard JV. Recommendations for the management OF galactosaemia. UK Galactosaemia Steering Group. *Arch Dis Child.* 1999;80(1):93–96.
3. Kiechle F, Q & A Column, *CAP Today*, September 2016. <http://www.captodayonline.com/qa-column-0916/>